Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | MC3R | P41968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324262 | 0.78 | MKNK1 (0.36) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL3379743 | 0.78 | ADORA3 (0.32) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL2826271 | 0.78 | MKNK1 (0.39) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL3101639 | 0.78 | NAPRT (0.34) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL2468463 | 0.76 | SIRT6 (0.34) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL2826536 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL3949975 | 0.72 | ADORA3 (0.31) | ADORA3TSHRMC4RADRA1AMC3R | |
| SCHEMBL2067479 | 0.72 | CDC7 (0.39) | — | |
| SCHEMBL4777551 | 0.72 | MYC (0.33) | — | |
| SCHEMBL2437411 | 0.72 | HTT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788326-B1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2019-04-24 | — | — | EP | claimed |
| US-9452120-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-27 | — | — | US | claimed |
| EP-2788326-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2014-10-15 | — | — | EP | claimed |
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | claimed |
| WO-2013064681-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-10 | — | — | WO | claimed |
| EP-2788326-B1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RES & DEV (FR) | 2019-04-24 | — | — | EP | disclosed |
| US-9732044-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-15 | — | — | US | disclosed |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-03-09 | — | — | US | disclosed |
| US-9452120-B2 | N-(pyrid-4-yl)amides and N-(pyrimidin-4-yl)amides and their pharmaceutical and cosmetic use | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2788326-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | Galderma Research & Development (FR) | 2014-10-15 | — | — | EP | disclosed |
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-21 | — | — | US | disclosed |
| WO-2013064681-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234245-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | NR5A1, AR, CYP19A1 | ADORA3 648/4885TSHR 358/4885MC4R 136/4885 |
| US-20170066725-A1 | N-(PYRID-4-YL)AMIDES AND N-(PYRIMIDIN-4-YL)AMIDES AND THEIR PHARMACEUTICAL AND COSMETIC USE | AR, NR5A1, PPARA | ADORA3 528/4885TSHR 237/4885MC4R 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.